GlassScriptPhysician profile
Sagari Bette
NPI 1043655657
$120,834.27
in general payments reported to CMS, 2019-2025
32 companies · $63K in 2025
The $63K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,145 · 2020: $2,567 · 2021: $7,613 · 2022: $8,678 · 2023: $16K · 2024: $17K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Honoraria: $13K · Travel and Lodging: $12K · Food and Beverage: $6,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,874.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,219.89 |
| Honoraria | $13,060.00 |
| Travel and Lodging | $11,845.09 |
| Food and Beverage | $6,832.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $25,107.13 | 2019-2025 | Nourianz |
| Abbvie INC. | $22,630.59 | 2020-2025 | Duopa, Botox |
| Merz Pharmaceuticals, LLC | $22,420.00 | 2021-2025 | Inbrija, Xeomin |
| Mdd US Operations, LLC | $20,469.18 | 2019-2025 | Gocovri, Apokyn, Apokyn |
| Amneal Pharmaceuticals LLC | $12,789.32 | 2019-2025 | Rytary, Ongentys, Crexont |
| Medtronic USA, INC. | $6,250.00 | 2019 | |
| Allergan, INC. | $5,879.37 | 2021 | |
| Acadia Pharmaceuticals INC | $1,047.94 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $938.20 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acorda Therapeutics, INC | $869.42 | 2019-2024 | Inbrija |
| Neurocrine Biosciences, INC. | $637.96 | 2019-2025 | Ingrezza, Ongentys |
| Adamas Pharmaceuticals, INC. | $292.19 | 2020-2021 | |
| Ipsen Innovation | $265.75 | 2025 | |
| Boston Scientific Corporation | $156.33 | 2019-2025 | General - Dbs |
| Ipsen Biopharmaceuticals, INC | $139.94 | 2024 | Dysport |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $131.72 | 2021-2022 | |
| Lundbeck LLC | $115.62 | 2019-2020 | |
| Eisai INC. | $107.52 | 2023-2025 | |
| Ucb, INC. | $88.01 | 2019-2021 | |
| Avion Pharmaceuticals | $78.30 | 2022-2023 | Dhivy |
| Biogen, INC. | $71.10 | 2024-2025 | Skyclarys |
| Azurity Pharmaceuticals, INC. | $58.46 | 2024 | Horizant |
| Cala Health, INC. | $57.77 | 2022-2023 | Cala Trio, Cala Kiq |
| Lilly USA, LLC | $48.78 | 2023-2024 | Amyvid |
| Abbott Laboratories | $43.52 | 2023-2025 | Infinity |
| Medtronic, INC. | $34.34 | 2025 | |
| Sage Therapeutics, LLC | $33.28 | 2020 | |
| Arbor Pharmaceuticals, INC. | $20.16 | 2021 | |
| Almatica Pharma LLC | $17.92 | 2023 | Gralise |
| Vertical Pharmaceuticals, LLC | $17.84 | 2019 | |
| Revance Therapeutics, INC. | $16.61 | 2025 | Daxxify |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagari Bette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.